Prime Medicine (PRME) Revenue & Revenue Breakdown
Prime Medicine Revenue Highlights
Latest Revenue (Y)
$2.98M
Latest Revenue (Q)
$39.31M
Main Segment (Y)
Reportable Segment
Prime Medicine Revenue by Period
Prime Medicine Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-12-31 | $2.98M | 100.00% |
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | -100.00% |
2020-12-31 | $5.21M | 100.00% |
2019-12-31 | - | - |
Prime Medicine generated $2.98M in revenue during NA 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Prime Medicine Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $39.31M | 6551.78% |
2024-03-31 | $591.00K | 100.00% |
2023-12-31 | - | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | - |
Prime Medicine generated $39.31M in revenue during Q2 2024, up 6551.78% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Prime Medicine Revenue Breakdown
Prime Medicine Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 24 |
---|---|
Reportable Segment | $2.98M |
Latest
Prime Medicine's latest annual revenue breakdown by segment (product or service), as of Dec 24: Reportable Segment (100.00%).
Prime Medicine Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
RPRX | Royalty Pharma | $2.26B | $564.69M |
BPMC | Blueprint Medicines | $508.82M | $128.18M |
DNA | Ginkgo Bioworks | $227.04M | $89.05M |
CRSP | CRISPR Therapeutics | $37.31M | $602.00K |
VERV | Verve Therapeutics | $32.33M | $6.87M |
RLAY | Relay Therapeutics | $10.01M | - |
IPSC | Century Therapeutics | $6.59M | $791.00K |
PRME | Prime Medicine | $2.98M | $39.31M |
OCEA | Ocean Biomedical | - | - |
NTLA | Intellia Therapeutics | - | $9.11M |
EDIT | Editas Medicine | - | - |
SANA | Sana Bio | - | - |
CRBU | Caribou Biosciences | - | $3.46M |
BEAM | Beam Therapeutics | - | $14.27M |